Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cleary

Showing results (431-440 of 445) with videos related to

Pageof 45
Sort By:
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
Cancer Research|December 2, 2022
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral HeterogeneityHannah L Williams, Andressa Dias Costa, Jinming Zhang, et al.
Cancer Discovery|May 12, 2025
Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targetsVindhya Vijay, Negin Karisani, Lei Shi, et al.
The Journal of Experimental Medicine|February 20, 2003
Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implicationsClaire Fieschi, Stéphanie Dupuis, Emilie Catherinot, et al.
JCI Insight|November 25, 2016
Institutional implementation of clinical tumor profiling on an unselected cancer populationLynette M Sholl, Khanh Do, Priyanka Shivdasani, et al.
JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2024
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal CancerHarshabad Singh, Pranshu Sahgal, Kevin Kapner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket TrialPetros Grivas, Elena Garralda, Funda Meric-Bernstam, et al.
JCO Precision Oncology|January 12, 2023
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal CancerRachel B Keller, Tali Mazor, Lynette Sholl, et al.
Cell|December 10, 2021
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancerSrivatsan Raghavan, Peter S Winter, Andrew W Navia, et al.
Pageof 45

Showing results (431-440 of 445) with videos related to

Sort By:
Pageof 45
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
Cancer Research|December 2, 2022
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral HeterogeneityHannah L Williams, Andressa Dias Costa, Jinming Zhang, et al.
Cancer Discovery|May 12, 2025
Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targetsVindhya Vijay, Negin Karisani, Lei Shi, et al.
The Journal of Experimental Medicine|February 20, 2003
Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implicationsClaire Fieschi, Stéphanie Dupuis, Emilie Catherinot, et al.
JCI Insight|November 25, 2016
Institutional implementation of clinical tumor profiling on an unselected cancer populationLynette M Sholl, Khanh Do, Priyanka Shivdasani, et al.
JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2024
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal CancerHarshabad Singh, Pranshu Sahgal, Kevin Kapner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket TrialPetros Grivas, Elena Garralda, Funda Meric-Bernstam, et al.
JCO Precision Oncology|January 12, 2023
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal CancerRachel B Keller, Tali Mazor, Lynette Sholl, et al.
Cell|December 10, 2021
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancerSrivatsan Raghavan, Peter S Winter, Andrew W Navia, et al.
Pageof 45